Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

ACT IV trial investigators

doi:10.1016/S1470-2045(17)30517-X

Scientific article

English

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

ContributorsACT IV trial investigators

CollaboratorsDietrich, Pierre-Yves

Published inThe Lancet Oncology, vol. 18, no. 10, p. 1373-1385

Publication date2017

Abstract

Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Immunothérapie des cancers (42)

Citation (ISO format)

ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. In: The Lancet Oncology, 2017, vol. 18, n° 10, p. 1373–1385. doi: 10.1016/S1470-2045(17)30517-X

Article (Published version)

Supplemental data

Identifiers

PID : unige:97075
DOI : 10.1016/S1470-2045(17)30517-X
PMID : 28844499

Journal ISSN1470-2045

431views

1downloads

Creation26/09/2017 15:55:00

First validation26/09/2017 15:55:00

Update15/03/2023 02:03:45

Status update15/03/2023 02:03:45

Last indexation31/10/2024 07:53:16

Archive ouverte UNIGE

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Technical informations